- 3.4Impact Factor
- 9.9CiteScore
- 19 daysTime to First Decision
Journal History
| 2013 | The inaugural issue was released. Vaccines was published as a quarterly journal. |
| 2015 | Vaccines was indexed in Emerging Sources Citation Index (ESCI)—Web of Science (Clarivate Analytics), starting with Volume 1 (Issue 1). Vaccines was indexed in Scopus (Elsevier), starting with Volume 1 (Issue 1). Vaccines was indexed in PubMed—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). |
| 2017 | Vaccines announced the first edition of the Travel Awards. The journal Twitter account was established. |
| 2018 | Vaccines was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 4 (Issue 1). |
| 2019 | Vaccines received its first Impact Factor (4.76). The journal ranks 39/158 (Q1) in the 'Immunology' category and 25/136 (Q1) in the "Medicine, Research & Experimental" category. |
| 2020 | Vaccines published its 1000th paper. Vaccines established the following sections: -Vaccine Adjuvants; -Attenuated/Inactivated/Live and Vectored Vaccines; -Clinical Immunology; -Cellular/Molecular Immunology; -Pathogens-host Immune Interface; -Human Papillomavirus Vaccines; -Hepatitis Virus Vaccines. |
| 2021 | Vaccines established the following sections: -COVID-19 Vaccines and Vaccination; -Vaccination Optimization; -DNA and mRNA Vaccines. |
| 2022 | The year 2022 marked the 10th Anniversary of Vaccines. |
| 2025 | Vaccines against Infectious Diseases was discontinued. Epidemiology was renamed as Epidemiology and Vaccination. Human Vaccines and Public Health was renamed as Vaccines and Public Health. Pathogens-host Immune Interface was renamed as Pathogens-Host Immune Boundaries. DNA and mRNA Vaccines was renamed as Nucleic Acid (DNA and mRNA) Vaccines. Therapeutic Vaccines and Antibody Therapeutics was merged with Cancer Vaccines and Immunotherapy to create a new section Vaccination Against Cancer and Chronic Diseases. Vaccine Adjuvants was merged with Attenuated/Inactivated/Live and Vectored Vaccines to create a new section Vaccine Design, Development, and Delivery. Innate and Adaptive Immunity in Vaccination and Clinical Immuology were merged with Cellular/Molecular Immunology to create a new section Vaccines, Clinical Advancement, and Associated Immunology. Vaccine Efficacy and Safety was merged with Vaccination Optimization to create a new section Vaccine Advancement, Efficacy and Safety. -Vaccines against Tropical and other Infectious Diseases was renamed as Vaccines Against Tropical and Other Infectious Diseases. |
Editor-in-Chief
| 2013–2019 | Editor-in-Chief: Prof. Dr. Diane M. Harper |
| 2019–2025 | Editor-in-Chief: Prof. Dr. Ralph A. Tripp |
| 2026–Present | Editor-in-Chief: Prof. Dr. Ger Rijkers |
Section Editor-in-Chief
| 2019–2025 | Section Editor-in-Chief: Prof. Dr. Giuseppe La Torre for the section on Epidemiology |
| Section Editor-in-Chief: Prof. Dr. Subbaya Subramanian for the section on Cancer Vaccines and Immunotherapy | |
| Section Editor-in-Chief: Prof. Dr. Martin F. Bachmann for the section on Therapeutic Vaccines and Antibody Therapeutics | |
| 2019–present | Section Editor-in-Chief: Dr. Romain Paillot for the section on Veterinary Vaccines |
| Section Editor-in-Chief: Prof. Dr. Nirbhay Kumar for the section on Vaccines against (re)emerging and Tropical Infections Diseases | |
| 2020–2025 | Section Editor-in-Chief: Dr. Eduardo Gomez-Casado for the section on Vaccine Adjuvants |
| Section Editor-in-Chief: Prof. Dr. Giampiero Girolomoni for the section on Clinical Immunology | |
| Section Editor-in-Chief: Prof. Dr. Hans-Peter Hartung for the section on Cellular/Molecular Immunology | |
| Section Editor-in-Chief: Dr. François Meurens for the section on Pathogens-host Immune Interface | |
| 2020–present | Section Editor-in-Chief: Dr. Yee-Joo Tan for the section on Hepatitis Virus Vaccines |
| Section Editor-in-Chief: Prof. Dr. Michael Bukrinsky for the section on HIV Vaccines | |
| 2021–2023 | Section Editor-in-Chief: Dr. Ralph J. DiClemente for the section on Vaccines and Society |
| 2021–2025 | Section Editor-in-Chief: Prof. Dr. Hinh Ly for the section on Innate and Adaptive Immunity in Vaccination |
| Section Editor-in-Chief: Dr. Jorge H. Leitão for the section on DNA and mRNA Vaccines | |
| Section Editor-in-Chief: Prof. Dr. Amine A. Kamen for the section on Attenuated/Inactivated/Live and Vectored Vaccines | |
| 2021–present | Section Editor-in-Chief: Prof. Dr. Luis Martinez-Sobrido for the section on COVID-19 Vaccines and Vaccination |
| 2023–2025 | Section Editor-in-Chief: Dr. Pedro Plans-Rubió for the section on Vaccine Efficacy and Safety |
| Section Editor-in-Chief: Dr. Christian Napoli for the section on Human Vaccines and Public Health |
|
| 2025–present | Section Editor-in-Chief: Prof. Dr. Subbaya Subramanian for the section on Vaccination Against Cancer and Chronic Diseases |
| Section Editor-in-Chief: Prof. Dr. Martin F. Bachmann for the section on Vaccination Against Cancer and Chronic Diseases | |
| Section Editor-in-Chief: Dr. Eduardo Gomez-Casado for the section on Vaccine Design, Development, and Delivery | |
| Section Editor-in-Chief: Prof. Dr. Hans-Peter Hartung for the section on Vaccines, Clinical Advancement, and Associated Immunology | |
| Section Editor-in-Chief: Dr. François Meurens for the section on Pathogens-Host Immune Boundaries | |
| Section Editor-in-Chief: Dr. Pedro Plans-Rubió for the section on Vaccine Advancement, Efficacy and Safety | |
| Section Editor-in-Chief: Dr. Jorge H. Leitão for the section on Nucleic Acid (DNA and mRNA) Vaccines | |
| Section Editor-in-Chief: Dr. Christian Napoli for the section on Vaccines and Public Health | |
| 2026–present | Section Editor-in-Chief: Dr. James Galloway for the section on Epidemiology and Vaccination |
Vaccines - ISSN 2076-393X